Pamidronate increases bone mineral density in women with postmenopausal or steroid-induced osteoporosis
| Autor: | E, Cauza, M, Etemad, F, Winkler, U, Hanusch-Enserer, H, Hanusch-Enserer, G, Partsch, H, Noske, A, Dunky |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment Osteoporosis Anti-Inflammatory Agents Urology Pamidronate Drug Administration Schedule Bone Density Statistical significance medicine Steroid-induced osteoporosis Humans Pharmacology (medical) Infusions Intravenous Glucocorticoids Aged Pharmacology Bone mineral Diphosphonates biology business.industry Pamidronic acid Middle Aged Bisphosphonate medicine.disease Spine Surgery Postmenopause Menopause Treatment Outcome Osteocalcin biology.protein Female business medicine.drug |
| Zdroj: | Journal of Clinical Pharmacy and Therapeutics. 29:431-436 |
| ISSN: | 1365-2710 0269-4727 |
| DOI: | 10.1111/j.1365-2710.2004.00584.x |
| Popis: | Summary Introduction: We aimed to determine the efficacy and safety of a cyclic intravenous therapy with pamidronate in patients with postmenopausal or glucocorticoid-induced osteoporosis. Methods: We enrolled 86 Austrian female patients with postmenopausal (n = 69, mean age 68·13 ±1·14) or glucocorticoid-induced (n = 17, mean age 66·89 ± 2·03) osteoporosis defined as a T-score of |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|